TY - JOUR AU - Siegel, R. AU - Ma, J. AU - Zou, Z. PY - 2014 DA - 2014// TI - Cancer statistics, 2014 JO - CA Cancer J Clin VL - 64 UR - https://doi.org/10.3322/caac.21208 DO - 10.3322/caac.21208 ID - Siegel2014 ER - TY - JOUR AU - Heintz, A. P. AU - Odicino, F. AU - Maisonneuve, P. PY - 2006 DA - 2006// TI - Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer JO - Int J Gynaecol Obstet VL - 95 UR - https://doi.org/10.1016/S0020-7292(06)60033-7 DO - 10.1016/S0020-7292(06)60033-7 ID - Heintz2006 ER - TY - JOUR AU - Vaughan, S. AU - Coward, J. I. AU - Bast, R. C. PY - 2011 DA - 2011// TI - Rethinking ovarian cancer: recommendations for improving outcomes JO - Nat Rev Cancer VL - 11 UR - https://doi.org/10.1038/nrc3144 DO - 10.1038/nrc3144 ID - Vaughan2011 ER - TY - JOUR AU - Colombo, N. AU - Gorp, T. AU - Parma, G. PY - 2006 DA - 2006// TI - Ovarian cancer JO - Crit Rev Oncol Hematol VL - 60 UR - https://doi.org/10.1016/j.critrevonc.2006.03.004 DO - 10.1016/j.critrevonc.2006.03.004 ID - Colombo2006 ER - TY - JOUR AU - Armstrong, D. K. PY - 2002 DA - 2002// TI - Relapsed ovarian cancer: challenges and management strategies for a chronic disease JO - Oncologist VL - 7 UR - https://doi.org/10.1634/theoncologist.7-suppl_5-20 DO - 10.1634/theoncologist.7-suppl_5-20 ID - Armstrong2002 ER - TY - JOUR AU - Stuart, G. C. AU - Kitchener, H. AU - Bacon, M. PY - 2010 DA - 2010// TI - Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference JO - Int J Gynecol Cancer VL - 21 UR - https://doi.org/10.1097/IGC.0b013e31821b2568 DO - 10.1097/IGC.0b013e31821b2568 ID - Stuart2010 ER - TY - JOUR AU - Friedlander, M. AU - Trimble, E. AU - Tinker, A. PY - 2011 DA - 2011// TI - Clinical trials in recurrent ovarian cancer JO - Int J Gynecol Cancer VL - 21 UR - https://doi.org/10.1097/IGC.0b013e31821bb8aa DO - 10.1097/IGC.0b013e31821bb8aa ID - Friedlander2011 ER - TY - JOUR AU - Pujade-Lauraine, E. PY - 2012 DA - 2012// TI - How to approach patients in relapse JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds358 DO - 10.1093/annonc/mds358 ID - Pujade-Lauraine2012 ER - TY - JOUR AU - Hall, M. AU - Rustin, G. PY - 2011 DA - 2011// TI - Recurrent ovarian cancer: when and how to treat JO - Curr Oncol Rep VL - 13 UR - https://doi.org/10.1007/s11912-011-0199-3 DO - 10.1007/s11912-011-0199-3 ID - Hall2011 ER - TY - JOUR AU - Colombo, N. AU - Gore, M. PY - 2007 DA - 2007// TI - Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy JO - Crit Rev Oncol Hematol VL - 64 UR - https://doi.org/10.1016/j.critrevonc.2007.04.004 DO - 10.1016/j.critrevonc.2007.04.004 ID - Colombo2007 ER - TY - JOUR AU - Parmar, M. K. AU - Ledermann, J. A. AU - Colombo, N. PY - 2003 DA - 2003// TI - Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/ AGO-OVAR-2.2 trial JO - Lancet VL - 361 UR - https://doi.org/10.1016/S0140-6736(03)13718-X DO - 10.1016/S0140-6736(03)13718-X ID - Parmar2003 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Wagner, U. AU - Aavall-Lundqvist, E. PY - 2010 DA - 2010// TI - Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.7519 DO - 10.1200/JCO.2009.25.7519 ID - Pujade-Lauraine2010 ER - TY - JOUR AU - Monk, B. J. AU - Coleman, R. L. PY - 2009 DA - 2009// TI - Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds JO - Int J Gynecol Cancer VL - 19 UR - https://doi.org/10.1111/IGC.0b013e3181c104fa DO - 10.1111/IGC.0b013e3181c104fa ID - Monk2009 ER - TY - JOUR AU - Bast, R. C. AU - Hennessy, B. AU - Mills, G. B. PY - 2009 DA - 2009// TI - The biology of ovarian cancer: new opportunities for translation JO - Nat Rev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2644 DO - 10.1038/nrc2644 ID - Bast2009 ER - TY - JOUR AU - Romero, I. AU - Sun, C. C. AU - Wong, K. K. PY - 2013 DA - 2013// TI - Low-grade serous carcinoma: new concepts and emerging therapies JO - Gynecol Oncol VL - 130 UR - https://doi.org/10.1016/j.ygyno.2013.05.021 DO - 10.1016/j.ygyno.2013.05.021 ID - Romero2013 ER - TY - JOUR PY - 2011 DA - 2011// TI - Integrated genomic analyses of ovarian carcinoma JO - Nature VL - 474 UR - https://doi.org/10.1038/nature10166 DO - 10.1038/nature10166 ID - ref16 ER - TY - JOUR AU - Yang, D. AU - Khan, S. AU - Sun, Y. PY - 2011 DA - 2011// TI - Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer JO - JAMA VL - 306 UR - https://doi.org/10.1001/jama.2011.1456 DO - 10.1001/jama.2011.1456 ID - Yang2011 ER - TY - JOUR AU - Majdak, E. J. AU - Debniak, J. AU - Milczek, T. PY - 2005 DA - 2005// TI - Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma JO - Cancer VL - 104 UR - https://doi.org/10.1002/cncr.21276 DO - 10.1002/cncr.21276 ID - Majdak2005 ER - TY - JOUR AU - Bolton, K. L. AU - Chenevix-Trench, G. AU - Goh, C. PY - 2012 DA - 2012// TI - Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer JO - JAMA VL - 307 UR - https://doi.org/10.1001/jama.2012.20 DO - 10.1001/jama.2012.20 ID - Bolton2012 ER - TY - JOUR AU - Varga, D. AU - Deniz, M. AU - Schwentner, L. PY - 2013 DA - 2013// TI - Ovarian cancer: in search of better marker systems based on DNA repair defects JO - Int J Mol Sci VL - 14 UR - https://doi.org/10.3390/ijms14010640 DO - 10.3390/ijms14010640 ID - Varga2013 ER - TY - JOUR AU - Tavecchio, M. AU - Simone, M. AU - Erba, E. PY - 2008 DA - 2008// TI - Role of homologous recombination in trabectedin-induced DNA damage JO - Eur J Cancer VL - 44 UR - https://doi.org/10.1016/j.ejca.2008.01.003 DO - 10.1016/j.ejca.2008.01.003 ID - Tavecchio2008 ER - TY - JOUR AU - Cuevas, C. AU - Francesch, A. PY - 2009 DA - 2009// TI - Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem JO - Nat Prod Rep VL - 26 UR - https://doi.org/10.1039/b808331m DO - 10.1039/b808331m ID - Cuevas2009 ER - TY - JOUR AU - Pommier, Y. AU - Kohlhagen, G. AU - Bailly, C. PY - 1996 DA - 1996// TI - DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata JO - Biochemistry VL - 35 UR - https://doi.org/10.1021/bi960306b DO - 10.1021/bi960306b ID - Pommier1996 ER - TY - JOUR AU - Erba, E. AU - Cavallaro, E. AU - Damia, G. PY - 2004 DA - 2004// TI - The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring JO - Oncol Res VL - 14 ID - Erba2004 ER - TY - JOUR AU - Zewail-Foote, M. AU - Hurley, L. H. PY - 1999 DA - 1999// TI - Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove JO - J Med Chem VL - 42 UR - https://doi.org/10.1021/jm990241l DO - 10.1021/jm990241l ID - Zewail-Foote1999 ER - TY - JOUR AU - D’Incalci, M. AU - Galmarini, C. M. PY - 2010 DA - 2010// TI - A review of trabectedin (ET-743): a unique mechanism of action JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-10-0263 DO - 10.1158/1535-7163.MCT-10-0263 ID - D’Incalci2010 ER - TY - JOUR AU - Pardo, B. AU - Salazar, R. AU - Ciruelos, E. PY - 2012 DA - 2012// TI - Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function JO - Med Oncol VL - 29 UR - https://doi.org/10.1007/s12032-011-9979-8 DO - 10.1007/s12032-011-9979-8 ID - Pardo2012 ER - TY - JOUR AU - Vidal, L. AU - Magem, M. AU - Barlow, C. PY - 2012 DA - 2012// TI - Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-010-9559-3 DO - 10.1007/s10637-010-9559-3 ID - Vidal2012 ER - TY - JOUR AU - Campo, J. M. AU - Sessa, C. AU - Krasner, C. N. PY - 2013 DA - 2013// TI - Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials JO - Med Oncol VL - 30 UR - https://doi.org/10.1007/s12032-012-0435-1 DO - 10.1007/s12032-012-0435-1 ID - Campo2013 ER - TY - JOUR AU - Sessa, C. AU - Braud, F. AU - Perotti, A. PY - 2005 DA - 2005// TI - Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.09.032 DO - 10.1200/JCO.2005.09.032 ID - Sessa2005 ER - TY - JOUR AU - Krasner, C. N. AU - McMeekin, D. S. AU - Chan, S. PY - 2007 DA - 2007// TI - A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens JO - Br J Cancer VL - 97 UR - https://doi.org/10.1038/sj.bjc.6604088 DO - 10.1038/sj.bjc.6604088 ID - Krasner2007 ER - TY - JOUR AU - Campo, J. M. AU - Roszak, A. AU - Bidzinski, M. PY - 2009 DA - 2009// TI - Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer JO - Ann Oncol VL - 20 UR - https://doi.org/10.1093/annonc/mdp198 DO - 10.1093/annonc/mdp198 ID - Campo2009 ER - TY - JOUR AU - Monk, B. J. AU - Herzog, T. J. AU - Kaye, S. B. PY - 2010 DA - 2010// TI - Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.4037 DO - 10.1200/JCO.2009.25.4037 ID - Monk2010 ER - TY - JOUR AU - Monk, B. J. AU - Herzog, T. J. AU - Kaye, S. B. PY - 2012 DA - 2012// TI - Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2012.04.001 DO - 10.1016/j.ejca.2012.04.001 ID - Monk2012 ER - TY - JOUR AU - Poveda, A. AU - Ray-Coquard, I. AU - Romero, I. PY - 2014 DA - 2014// TI - Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin JO - Cancer Treat Rev VL - 40 UR - https://doi.org/10.1016/j.ctrv.2013.08.001 DO - 10.1016/j.ctrv.2013.08.001 ID - Poveda2014 ER - TY - JOUR AU - Poveda, A. AU - Vergote, I. AU - Tjulandin, S. PY - 2011 DA - 2011// TI - Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdq352 DO - 10.1093/annonc/mdq352 ID - Poveda2011 ER - TY - JOUR AU - Donald, S. AU - Verschoyle, R. D. AU - Greaves, P. PY - 2003 DA - 2003// TI - Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat JO - Cancer Res VL - 63 ID - Donald2003 ER - TY - JOUR AU - Lebedinsky, C. AU - Gomez, J. AU - Park, Y. C. PY - 2011 DA - 2011// TI - Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis JO - Cancer Chemother Pharmacol VL - 68 UR - https://doi.org/10.1007/s00280-011-1614-z DO - 10.1007/s00280-011-1614-z ID - Lebedinsky2011 ER - TY - JOUR AU - Cesne, A. AU - Yovine, A. AU - Blay, J. Y. PY - 2012 DA - 2012// TI - A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials JO - Invest New Drugs VL - 30 UR - https://doi.org/10.1007/s10637-011-9662-0 DO - 10.1007/s10637-011-9662-0 ID - Cesne2012 ER - TY - JOUR AU - Lorusso, D. AU - Ferrandina, G. AU - Pignata, S. PY - 2014 DA - 2014// TI - Trabectedin in patients with BRCA mutated and BRCAness phenotype advanced ovarian cancer (AOC): phase II prospective MITO-15 study JO - Ann Oncol VL - 25 ID - Lorusso2014 ER - TY - STD TI - Poveda A, Berton-Rigaud D, Laure Ray-Coquard I, et al. Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: results of a two-stage, controlled phase II study. J Clin Oncol, 2014,32:abstr 5505. ID - ref41 ER - TY - JOUR AU - Kelland, L. PY - 2007 DA - 2007// TI - The resurgence of platinum-based cancer chemotherapy JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2167 DO - 10.1038/nrc2167 ID - Kelland2007 ER - TY - JOUR AU - Hoeijmakers, J. H. PY - 2001 DA - 2001// TI - Genome maintenance mechanisms for preventing cancer JO - Nature VL - 411 UR - https://doi.org/10.1038/35077232 DO - 10.1038/35077232 ID - Hoeijmakers2001 ER - TY - JOUR AU - Takebayashi, Y. AU - Nakayama, K. AU - Kanzaki, A. PY - 2001 DA - 2001// TI - Loss of heterozygosity of nucleotide excision repair factors in sporadic ovarian, colon and lung carcinomas: implication for their roles of carcinogenesis in human solid tumors JO - Cancer Lett VL - 174 UR - https://doi.org/10.1016/S0304-3835(01)00690-5 DO - 10.1016/S0304-3835(01)00690-5 ID - Takebayashi2001 ER - TY - JOUR AU - Fu, D. AU - Calvo, J. A. AU - Samson, L. D. PY - 2012 DA - 2012// TI - Balancing repair and tolerance of DNA damage caused by alkylating agents JO - Nat Rev Cancer VL - 12 ID - Fu2012 ER - TY - JOUR AU - Damia, G. AU - Silvestri, S. AU - Carrassa, L. PY - 2001 DA - 2001// TI - Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways JO - Int J Cancer VL - 92 UR - https://doi.org/10.1002/ijc.1221 DO - 10.1002/ijc.1221 ID - Damia2001 ER - TY - JOUR AU - Erba, E. AU - Bergamaschi, D. AU - Bassano, L. PY - 2001 DA - 2001// TI - Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action JO - Eur J Cancer VL - 37 UR - https://doi.org/10.1016/S0959-8049(00)00357-9 DO - 10.1016/S0959-8049(00)00357-9 ID - Erba2001 ER - TY - JOUR AU - Takebayashi, Y. AU - Pourquier, P. AU - Zimonjic, D. B. PY - 2001 DA - 2001// TI - Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair JO - Nat Med VL - 7 UR - https://doi.org/10.1038/91008 DO - 10.1038/91008 ID - Takebayashi2001 ER - TY - JOUR AU - Soares, D. G. AU - Poletto, N. P. AU - Bonatto, D. PY - 2005 DA - 2005// TI - Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways JO - Biochem Pharmacol VL - 70 UR - https://doi.org/10.1016/j.bcp.2005.04.013 DO - 10.1016/j.bcp.2005.04.013 ID - Soares2005 ER - TY - JOUR AU - Damia, G. AU - Imperatori, L. AU - Stefanini, M. PY - 1996 DA - 1996// TI - Sensitivity of cho mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents JO - Int J Cancer VL - 66 UR - https://doi.org/3.0.CO;2-Z DO - 3.0.CO;2-Z ID - Damia1996 ER - TY - JOUR AU - Herrero, A. B. AU - Martin-Castellanos, C. AU - Marco, E. PY - 2006 DA - 2006// TI - Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-0179 DO - 10.1158/0008-5472.CAN-06-0179 ID - Herrero2006 ER - TY - JOUR AU - Soares, D. G. AU - Escargueil, A. E. AU - Poindessous, V. PY - 2007 DA - 2007// TI - Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743 JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0609877104 DO - 10.1073/pnas.0609877104 ID - Soares2007 ER - TY - JOUR AU - Stevens, E. V. AU - Nishizuka, S. AU - Antony, S. PY - 2008 DA - 2008// TI - Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-07-0192 DO - 10.1158/1535-7163.MCT-07-0192 ID - Stevens2008 ER - TY - JOUR AU - Furuta, T. AU - Ueda, T. AU - Aune, G. PY - 2002 DA - 2002// TI - Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells JO - Cancer Res VL - 62 ID - Furuta2002 ER - TY - JOUR AU - Turner, N. AU - Tutt, A. AU - Ashworth, A. PY - 2004 DA - 2004// TI - Hallmarks of ‘BRCAness’ in sporadic cancers JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1457 DO - 10.1038/nrc1457 ID - Turner2004 ER - TY - JOUR AU - Lord, C. J. AU - Garrett, M. D. AU - Ashworth, A. PY - 2006 DA - 2006// TI - Targeting the double-strand DNA break repair pathway as a therapeutic strategy JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-1269 DO - 10.1158/1078-0432.CCR-06-1269 ID - Lord2006 ER - TY - JOUR AU - Monk, B. J. AU - Kaye, S. B. AU - Poveda, A. PY - 2014 DA - 2014// TI - Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial JO - Gynecol Oncol VL - 132 UR - https://doi.org/10.1016/j.ygyno.2013.10.032 DO - 10.1016/j.ygyno.2013.10.032 ID - Monk2014 ER - TY - JOUR AU - Stracker, T. H. AU - Petrini, J. H. PY - 2011 DA - 2011// TI - The MRE11 complex: starting from the ends JO - Nat Rev Mol Cell Biol VL - 12 UR - https://doi.org/10.1038/nrm3047 DO - 10.1038/nrm3047 ID - Stracker2011 ER - TY - JOUR AU - D’Incalci, M. AU - Badri, N. AU - Galmarini, C. M. PY - 2014 DA - 2014// TI - Trabectedin, a drug acting on both cancer cells and the tumour microenvironment JO - Br J Cancer VL - 111 UR - https://doi.org/10.1038/bjc.2014.149 DO - 10.1038/bjc.2014.149 ID - D’Incalci2014 ER - TY - JOUR AU - Germano, G. AU - Frapolli, R. AU - Belgiovine, C. PY - 2013 DA - 2013// TI - Role of macrophage targeting in the antitumor activity of trabectedin JO - Cancer Cell VL - 23 UR - https://doi.org/10.1016/j.ccr.2013.01.008 DO - 10.1016/j.ccr.2013.01.008 ID - Germano2013 ER - TY - JOUR AU - Allavena, P. AU - Signorelli, M. AU - Chieppa, M. PY - 2005 DA - 2005// TI - Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-04-4037 DO - 10.1158/0008-5472.CAN-04-4037 ID - Allavena2005 ER - TY - JOUR AU - Giandomenico, S. AU - Frapolli, R. AU - Bello, E. PY - 2014 DA - 2014// TI - Mode of action of trabectedin in myxoid liposarcomas JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2013.462 DO - 10.1038/onc.2013.462 ID - Giandomenico2014 ER - TY - JOUR AU - Feuerhahn, S. AU - Giraudon, C. AU - Martinez-Diez, M. PY - 2011 DA - 2011// TI - XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids JO - Chem Biol VL - 18 UR - https://doi.org/10.1016/j.chembiol.2011.06.007 DO - 10.1016/j.chembiol.2011.06.007 ID - Feuerhahn2011 ER - TY - JOUR AU - Germano, G. AU - Frapolli, R. AU - Simone, M. PY - 2010 DA - 2010// TI - Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-2335 DO - 10.1158/0008-5472.CAN-09-2335 ID - Germano2010 ER -